N/A N=161 CEP249 Pediatric Accuracy Study
Insulin Requiring Diabetes
Primary: Enlite Sensor Accuracy Mean Absolute Relative Difference (MARD), With Lower Serial Number 530G Pump — 15.02 percentage of difference
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=191 Financial Incentives for Maintenance of Weight Loss
Obesity
Primary: Change in Weight From Baseline to 6 Months — -1.4; -2.8; -3.0 kilograms — p=>0.1
Phase 4 N=18 Opiates and Benzodiazepines on Driving
Driving Behavior
Primary: SDLP — 35.2; 49.8; 50.0; 33.5 centimeters
Phase 4 N=42 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism
Social Anxiety Disorder · Social Phobia · Alcohol Use Disorder
Primary: Social Anxiety Severity — 87; 93 units on a scale
Phase 2 N=60 A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients
Oedema, Pulmonary
Primary: Number of Participants With Vital Sign Values of Potential Clinical Concern in Healthy Participants — 0; 0; 8; 0 Participants
N/A N=200 Does a Patient Education Video Augment Pelvic Floor Physical Therapy Compliance?
Patient Compliance · Pelvic Floor Disorders
Primary: Number of Participants With Completed PT Visits — 47; 50; 11; 21 Participants — p=0.17
Phase 4 N=15 Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study)
Major Depressive Disorder
Primary: Change in Total MADRS (Montgomery Asberg Depression Rating Scale) Score — -18.45 units on a scale — p=<0.001
Phase 3 N=68 A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban
Bleeding
Primary: Efficacy: Percent Change From Baseline in Anti-fXa Activity at the Nadir (Parts I and II) — -20.71; -93.86; -32.70; -92.34 Percent change in anti-fXa activity — p=<0.0001
Phase 3 N=182 Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
Plaque-type Psoriasis
Primary: Psoriasis Area and Severity Index (PASI) 75 Response and Investigators' Global Assessment (IGA) Mod 2011 0 or 1 Response — 71.7; 86.7; 3.3; 53.3 Percentages of…
N/A N=82 Efficacy Study of FES Controlled by Electromyographic Signal for the Treatment of Upper Limb in Post-stroke Patients
Stroke
Primary: Change Score of ARAT Scale Between Two Time Points: Post-treatment vs Pre-treatment — 6.6; 5.0 score on a scale
N/A N=25 Silk'n HST Device Usability and Self Selection Study
Wrinkles
Primary: Usability Assessment — 25 Participants
Phase 2 N=81 Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer
HER2-normal
Primary: Percentage of Participants With Feasibility — 70.4; 60.0 Percentage of participants — p=0.4422
Phase 4 N=71 Oral Ketorolac for Pain Relief During IUD Insertion
Contraception
Primary: Pain Before, During and After IUD Placement — 4.1; 4.5; 0.4; 0.7 units on a scale — p=< 0.05
N/A N=60 Propofol Pharmacokinetics and Pharmacodynamics Modelling
Intravenous Anesthetic Agent Overdose
Primary: Plasma Propofol Concentration (mcg/mL) — 2.36; 3.12; 2.91 mcg/mL
Phase 4 N=61 Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)
Autistic Disorder
Primary: Changes in the Irritability Subscale of the Larger ABC (Abberent Behavior Checklist) That Occur From Baseline to 10 Weeks — 12.7; 14.1 units on a scale